SCHEMBL4437683

SCHEMBL4437683

Cc1c(C)c(S(=O)(=O)NC(=N)NCCC[C@H](NC(=O)c2cccc(Cc3ccccc3)c2)C(=O)O)c(C)c2c1OC(C)(C)CC2

nearest known ligand 0.47

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
PLG P00747 3/20 0.47
PLAU P00749 2/20 0.47
F10 P00742 2/20 0.47
KLKB1 P03952 1/20 0.47
F2 P00734 2/20 0.38
ST14 Q9Y5Y6 1/20 0.38
PPARG P37231 1/20 0.33
TACR2 P21452 1/20 0.32
AGTR2 P50052 1/20 0.32
KLK7 P49862 1/20 0.32
FNTA P49354 4/20 0.32
FNTB P49356 4/20 0.32
PGGT1B P53609 1/20 0.32
PRSS1 P07477 1/20 0.32
CA1 P00915 1/20 0.31
CA2 P00918 1/20 0.31
PADI6 Q6TGC4 1/20 0.31
GPR132 Q9UNW8 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4430680 0.94 PLG (0.44) PLGPLAUF10KLKB1F2
SCHEMBL4438546 0.88 PLG (0.40) PLGPLAUF10KLKB1F2
SCHEMBL4428164 0.88 PLG (0.39) PLGPLAUF10KLKB1F2
SCHEMBL4990632 0.87 PLG (0.42) PLGPLAUF10KLKB1F2
SCHEMBL4428247 0.86 PLG (0.40) PLGPLAUF10KLKB1F2
SCHEMBL4428156 0.85 PLG (0.39) PLGPLAUF10KLKB1F2
SCHEMBL4436533 0.85 PLG (0.39) PLGPLAUF10KLKB1F2
SCHEMBL4431517 0.85 PLG (0.39) PLGPLAUF10KLKB1F2
SCHEMBL4994106 0.85 PLG (0.41) PLGPLAUF10KLKB1F2
SCHEMBL4997179 0.84 PLG (0.39) PLGPLAUF10KLKB1F2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2125739-A1 MODULATORS OF C3A RECEPTOR AND METHODS OF USE THEREOF ENCYSIVE PHARMACEUTICALS, INC. (US) 2009-12-02 EP disclosed
US-20080188528-A1 Modulators of C3a receptor and methods of use thereof ENCYSIVE PHARMACEUTICALS, INC. 2008-08-07 US disclosed
WO-2008079371-A1 MODULATORS OF C3A RECEPTOR AND METHODS OF USE THEREOF ENCYSIVE PHARMACEUTICALS, INC. (US) 2008-07-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080188528-A1 Modulators of C3a receptor and methods of use thereof C3AR1, C5, C5AR1 PLG 52/4885PLAU 156/4885F10 432/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.